<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436731</url>
  </required_header>
  <id_info>
    <org_study_id>2022525</org_study_id>
    <nct_id>NCT04436731</nct_id>
  </id_info>
  <brief_title>Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity</brief_title>
  <official_title>Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with sleep apnea are at increased risk of developing cardiovascular disease - with
      women at potentially greater risk than men. Contributing mechanisms are not well understood,
      but may be related to how women respond to low oxygen and, given over 70% of patients with
      sleep apnea are obese, the impact of obesity. This project seeks to increase our
      understanding of mechanisms that may contribute to sex differences in the cardiovascular
      response to low oxygen with the hope that this knowledge will improve the efficacy of current
      therapies and support the discovery of novel therapeutics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forearm vascular conductance with intra-arterial drug infusion</measure>
    <time_frame>Continuous measurement of vascular conductance during infusion of each drug (final 3 min of normoxia and hypoxia).</time_frame>
    <description>Vascular conductance is an index of vascular tone and is measured using a technique called venous occlusion plethysmography.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Obesity</condition>
  <condition>Healthy</condition>
  <condition>Vasoconstriction</condition>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxia Exposure</intervention_name>
    <description>Systemic oxygen levels will be titrated by mixing nitrogen with air in a medical gas blender to attain steady arterial oxygen saturations of 80%.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine (0.0625 mcg/min/dL tissue) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
    <other_name>Phenylephrine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine (12.5 ng/min/dL tissue) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Norepinephrine (8 mg/min/dL tissue) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine</intervention_name>
    <description>Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
    <other_name>Phentolamine mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years of age (premenopausal)

          -  Healthy weight (BMI ≥18 and ≤25 kg/m2)

          -  Obese (BMI ≥30 kg/m2)

        Exclusion Criteria:

          -  Pregnancy, breastfeeding, oral hormonal contraceptive use

          -  Diagnosed sleep apnea or Oxygen desaturation index &gt;10 events/hr

          -  Current smoking/Nicotine use

          -  Increased risk of bleeding, pro-coagulant disorders, clotting disorders,
             anticoagulation therapy

          -  Nerve/neurologic disease

          -  Cardiovascular, hepatic, renal, respiratory disease

          -  Blood pressure ≥140/90 mmHg

          -  Diabetes, Polycystic ovarian syndrome

          -  Communication barriers

          -  Prescription medications, Sensitivity to lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer L Harper, B.S.</last_name>
    <phone>573-882-2544</phone>
    <email>harperjl@missouri.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Missouri-Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacqueline K Limberg, Ph.D.</last_name>
      <phone>573-882-2420</phone>
      <email>limbergj@missouri.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Jacqueline K Limberg, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

